Get in touch at adsales@samsung.comsamsungads.com
Source: Samsung Ads proprietary ACR data; IQVIA 2022 Campaign Report.
Dynamic strategies unlock
success across multiple lines
of business
Background
A leading pharmaceutical company aimed to extend the proven success of their RX initiatives to their
various OTC lines of business. Recognizing that OTC brands cater to a broader target audience, the
company turned to Samsung to develop a new strategy to not only reach this more general market, but
also achieve incremental reach against their traditional linear efforts.
Driving results
for a leading
pharma brand
RXStrategy
Leverage Samsung’s scale paired with healthcare
data segments and measurement solutions to reach
hyper-targeted, diagnosed audiences
Results
Audience Quality
CTV + diagnosed audiences proved to be highly
efficient in achieving diagnosed audience quality and
reaching diagnosed unique viewers.
OTCStrategy
Leverage CTV to reach a less-targeted audience at a
lower cost, while achieving incremental reach against
existing linear buys
Results
Outcomes
Across multiple OTC brands, Samsung Ads drove
significant incremental reach against linear
campaigns:
Efficiency
Samsung remained the most efficient partner on the
plan following the 2022 CTV campaign launch
Efficiency
The majority of impressions fell within the brand’s
target audience without the need to pay for
additional demo targeting
5.5%AQ score, above IQVIA’s
4.8 benchmark* for this
particular diagnosed
audience
7.3Kincremental new
patient office visits
Dental care brand 1:
32% incremental lift;
63% within A25-54
demo target vs.
linear’s 41%
Dental care brand 2:
43% incremental lift;
72% within A25-54 demo
target vs. linear’s 41%
Vaccine brand:
15% incremental lift;
70% within A50+
demo target vs.
linear’s 78%
Injectable
antiretroviralbrand:
11% incremental lift;
53% within A25-54 demo
target vs. linear’s 52%